Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases.

El-Senosy, Fatma M.; Abd El Aziz, Rasha Elsayed Mohamed; Kasim, Sammar Ahmed; Gad, Lamia Abdulbary; Hassan, Donia Ahmed; Sabry, Seham; El mancy, Ismail Mohamed; Shawky, Taiseer Ahmed; Mohamed, Ibrahim Ghounim Ramadan; Elmonier, Rady; Kotb, Essam; Abdul-Mohymen, Abeer Mohammed

<bold>Results: </bold>HD and CKD groups had significantly higher endocan levels when compared with control group (median (IQR): 519.0 (202.3-742.0) versus 409.0 (245.3-505.3) and 273.0 (168.0-395.5) ng/L, respectively). Also, HD patients had significantly higher endocan levels when compared with CKD levels. HD patients had significantly higher carotid intima-media thickness (CIMT) when compared with CKD patients (median (IQR): 0.80 (0.80-0.90) versus 0.75 (0.73-0.75) mm, p < 0.001). HD patients had significantly higher frequency of SCA when compared with CKD patients (46.7% versus 13.3%, p=0.005). Patients with SCA had significantly higher hsCRP (median (IQR): 36.5 (26.8-43.5) versus 24.0 (15.8-29.0) mg/dl) and endocan levels (697.0 (528.3-974.8) versus 222.5 (158.8-565.8) ng/L) when compared with patients without SCA. ROC curve analysis of endocan for identification of SCA in HD patients showed that at a cutoff of 380.5 ng/L, endocan has an AUC of 0.862 with a sensitivity and specificity of 92.9% and 68.7%, respectively.<bold>Conclusions: </bold>Serum endocan levels are related to SCA in HD patients. In addition, it is associated with the hyperinflammatory state in those patients.

International Journal of Clinical Practice, 2022, p1

1368-5031

Academic Journal

10.1155/2022/4524637